Literature DB >> 31046081

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

N Colombo1, C Sessa2, A du Bois3, J Ledermann4, W G McCluggage5, I McNeish6, P Morice7, S Pignata8, I Ray-Coquard9, I Vergote10, T Baert3, I Belaroussi7, A Dashora11, S Olbrecht10, F Planchamp12, D Querleu13.   

Abstract

The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO-ESGO consensus conference on ovarian cancer was held on 12-14 April 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO-ESGO consensus conference, together with a summary of evidence supporting each recommendation.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  adjuvant treatment; molecular biology; ovarian cancer; pathology; recurrent disease; surgery

Mesh:

Substances:

Year:  2019        PMID: 31046081     DOI: 10.1093/annonc/mdz062

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  155 in total

Review 1.  Low-grade Serous Tumors: Are We Making Progress?

Authors:  Nina Pauly; Sarah Ehmann; Enzo Ricciardi; Beyhan Ataseven; Mareike Bommert; Florian Heitz; Sonia Prader; Stephanie Schneider; Andreas du Bois; Philipp Harter; Thaïs Baert
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

2.  Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.

Authors:  Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan
Journal:  Adv Ther (Weinh)       Date:  2020-08-16

3.  Is there a role for immunotherapy in ovarian cancer?

Authors:  Gaia Giannone; Giorgio Valabrega
Journal:  Ann Transl Med       Date:  2019-12

Review 4.  The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.

Authors:  Chongzhen Guo; Chengda Yan; Lianyue Qu; Rongrong Du; Jianyang Lin
Journal:  Arch Gynecol Obstet       Date:  2020-11-21       Impact factor: 2.344

Review 5.  Laparotomy vs. minimally invasive surgery for ovarian cancer recurrence: a systematic review.

Authors:  Stefano Uccella; Massimo P Franchi; Stefano Cianci; Pier Carlo Zorzato; Francesca Bertoli; Salvatore Gueli Alletti; Fabio Ghezzi; Giovanni Scambia
Journal:  Gland Surg       Date:  2020-08

Review 6.  Narrative review of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer: a critical reappraisal of the current evidence.

Authors:  John Spiliotis; Anastasia Prodromidou
Journal:  J Gastrointest Oncol       Date:  2021-04

7.  Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.

Authors:  Jonathan A Ledermann; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew R Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Susana Banerjee; Jesus García-Donas; Elizabeth M Swisher; Terri Cameron; Lara Maloney; Sandra Goble; Robert L Coleman
Journal:  Lancet Oncol       Date:  2020-05       Impact factor: 41.316

8.  Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.

Authors:  Jan Philipp Ramspott; Thaïs Baert; Michelle Louise MacKintosh; Alexander Traut; Beyhan Ataseven; Mareike Bommert; Florian Heitz; Helmut Plett; Stephanie Schneider; Kai-Uwe Waltering; Sebastian Heikaus; Philipp Harter; Andreas du Bois
Journal:  Arch Gynecol Obstet       Date:  2021-03-04       Impact factor: 2.344

9.  [Ginsenoside 20(S)-Rg3 upregulates tumor suppressor VHL gene expression by suppressing DNMT3A-mediated promoter methylation in ovarian cancer cells].

Authors:  Lijie Wang; Xi Han; Xia Zheng; Yuanyuan Zhou; Huilian Hou; Wei Chen; Xu Li; Le Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

10.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.